Ekta Kapadia

945 total citations · 1 hit paper
24 papers, 575 citations indexed

About

Ekta Kapadia is a scholar working on Surgery, Oncology and Biotechnology. According to data from OpenAlex, Ekta Kapadia has authored 24 papers receiving a total of 575 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Surgery, 14 papers in Oncology and 13 papers in Biotechnology. Recurrent topics in Ekta Kapadia's work include Bladder and Urothelial Cancer Treatments (23 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cancer Research and Treatments (13 papers). Ekta Kapadia is often cited by papers focused on Bladder and Urothelial Cancer Treatments (23 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cancer Research and Treatments (13 papers). Ekta Kapadia collaborates with scholars based in United States, Japan and Netherlands. Ekta Kapadia's co-authors include Ashish M. Kamat, Hiroyuki Nishiyama, Kijoeng Nam, Tara L. Frenkl, Arjun Vasant Balar, Eric A. Singer, Edward Uchio, Ho Kyung Seo, Laurence E. Krieger and Dean F. Bajorin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Ekta Kapadia

23 papers receiving 569 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

2021 329 citations Arjun Vasant Balar, Ashish M. Kamat et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ekta Kapadia United States	8	511	224	120	102	83	24	575
Laurence E. Krieger Australia	8	447 0.9×	217 1.0×	109 0.9×	84 0.8×	92 1.1×	26	518
Armine K. Smith United States	9	424 0.8×	90 0.4×	73 0.6×	171 1.7×	128 1.5×	27	541
Truls Gårdmark Sweden	12	380 0.7×	185 0.8×	78 0.7×	105 1.0×	69 0.8×	48	522
Nicolás Flores Spain	10	489 1.0×	98 0.4×	92 0.8×	199 2.0×	62 0.7×	21	617
Kenta Ohnishi Japan	10	183 0.4×	145 0.6×	104 0.9×	34 0.3×	79 1.0×	16	372
Ashish M. Kamat United States	10	546 1.1×	109 0.5×	89 0.7×	175 1.7×	99 1.2×	15	576
Manuel Sierra Montesinos Spain	6	794 1.6×	169 0.8×	113 0.9×	251 2.5×	97 1.2×	13	839
Toshiki Tanikawa Japan	10	160 0.3×	107 0.5×	105 0.9×	30 0.3×	76 0.9×	39	349
Jesús Rodríguez-Molina Spain	7	797 1.6×	210 0.9×	123 1.0×	251 2.5×	123 1.5×	7	873
Óscar Rodríguez Spain	13	283 0.6×	65 0.3×	45 0.4×	90 0.9×	68 0.8×	27	347

Countries citing papers authored by Ekta Kapadia

Since Specialization

Citations

This map shows the geographic impact of Ekta Kapadia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ekta Kapadia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ekta Kapadia more than expected).

Fields of papers citing papers by Ekta Kapadia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ekta Kapadia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ekta Kapadia. The network helps show where Ekta Kapadia may publish in the future.

Co-authorship network of co-authors of Ekta Kapadia

This figure shows the co-authorship network connecting the top 25 collaborators of Ekta Kapadia. A scholar is included among the top collaborators of Ekta Kapadia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ekta Kapadia. Ekta Kapadia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kulkarni, Girish S., Thomas J. Guzzo, Philip H. Abbosh, et al.. (2025). Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review. Clinical Genitourinary Cancer. 23(3). 102313–102313. 1 indexed citations

Shore, Neal D., Hiroyuki Nishiyama, Shahrokh F. Shariat, et al.. (2024). Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.. Journal of Clinical Oncology. 42(4_suppl). TPS722–TPS722. 2 indexed citations

Kulkarni, Girish S., Shilpa Gupta, Andrea Necchi, et al.. (2024). Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.. Journal of Clinical Oncology. 42(4_suppl). TPS719–TPS719.

Gupta, Shilpa, Yasuhisa Fujii, Michiel Simon Van Der Heijden, et al.. (2024). Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 42(4_suppl). TPS720–TPS720. 3 indexed citations

Shore, Neal D., Shilpa Gupta, Girish S. Kulkarni, et al.. (2023). Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC).. Journal of Clinical Oncology. 41(6_suppl). TPS591–TPS591. 2 indexed citations

Shore, Neal D., Nicholas D. James, Michiel Simon Van Der Heijden, et al.. (2022). Abstract CT564: KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent chemoradiotherapy. Cancer Research. 82(12_Supplement). CT564–CT564. 3 indexed citations

Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2021). Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. The Lancet Oncology. 22(7). 919–930. 329 indexed citations breakdown →

Shariat, Shahrokh F., Gregory R. Steinberg, Ashish M. Kamat, et al.. (2021). 718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC). Annals of Oncology. 32. S723–S723. 1 indexed citations

Weickhardt, Andrew, Michiel Simon Van Der Heijden, Arjun Vasant Balar, et al.. (2021). Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.. Journal of Clinical Oncology. 39(6_suppl). TPS508–TPS508. 1 indexed citations

10.

Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2021). Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A.. Journal of Clinical Oncology. 39(6_suppl). 451–451. 7 indexed citations

11.

Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2020). Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.. Journal of Clinical Oncology. 38(15_suppl). 5041–5041. 23 indexed citations

12.

Boormans, Joost L., Ronald de Wit, Edward Uchio, et al.. (2020). Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG). European Urology Open Science. 19. e1173–e1174. 2 indexed citations

13.

Kamat, Ashish M., Neal D. Shore, Noah M. Hahn, et al.. (2019). Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.. Journal of Clinical Oncology. 37(15_suppl). TPS4591–TPS4591. 3 indexed citations

14.

Wit, Ronald de, Girish S. Kulkarni, Edward Uchio, et al.. (2019). Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057.. Journal of Clinical Oncology. 37(15_suppl). 4530–4530. 4 indexed citations

15.

Wit, Ronald de, Arjun Vasant Balar, Ashish M. Kamat, et al.. (2019). MP43-01 PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON–MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN. The Journal of Urology. 201(Supplement 4). 4 indexed citations

16.

Boormans, Joost L., Arjun Vasant Balar, Ronald de Wit, et al.. (2019). Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study. European Urology Supplements. 18(1). e758–e759. 1 indexed citations

17.

Balar, Arjun Vasant, Girish S. Kulkarni, Edward Uchio, et al.. (2019). Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).. Journal of Clinical Oncology. 37(7_suppl). 350–350. 80 indexed citations

18.

Kamat, Ashish M., Neal D. Shore, Noah M. Hahn, et al.. (2019). Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.. Journal of Clinical Oncology. 37(7_suppl). TPS502–TPS502. 4 indexed citations

19.

Wit, Ronald de, Girish S. Kulkarni, Edward Uchio, et al.. (2018). Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial. Annals of Oncology. 29. viii304–viii304. 9 indexed citations

20.

Kapadia, Ekta, Edward C.C. Wong, Evelio Perez‐Albuerne, & David A. Jacobsohn. (2015). Extracorporeal photopheresis performed on the CELLEX® compared with the UVAR‐XTS® instrument is more efficient and better tolerated in children with steroid‐refractory graft‐versus‐host disease. Pediatric Blood & Cancer. 62(8). 1485–1488. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact